Detalhe da pesquisa
1.
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
N Engl J Med
; 386(26): 2482-2494, 2022 06 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35657079
2.
Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study.
Blood
; 142(16): 1348-1358, 2023 10 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37369099
3.
Effectiveness of tixagevimab/cilgavimab in patients with hematological malignancies as a pre-exposure prophylaxis to prevent severe COVID-19: a Czech retrospective multicenter study.
Ann Hematol
; 103(3): 981-992, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38092996
4.
Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic.
Ann Hematol
; 102(1): 107-115, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36369497
5.
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Blood
; 136(18): 2038-2050, 2020 10 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-32731259
6.
Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study.
Haematologica
; 107(7): 1633-1642, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34407602
7.
Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world.
Eur J Haematol
; 109(2): 162-165, 2022 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-35502609
8.
Burkitt lymphoma-a retrospective analysis of data from the Registry of the Czech Lymphoma Study Group with external validation of the Burkitt lymphoma International Prognostic Index.
Neoplasma
; 69(6): 1466-1473, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36591807
9.
Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group.
Br J Haematol
; 193(4): 769-778, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33618437
10.
Rituximab, Cyclophosphamide and Dexamethasone (RCD) Chemoimmunotherapy for Relapsed Chronic Lymphocytic Leukaemia.
Eur J Clin Invest
; 51(4): e13421, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33022756
11.
Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306).
Br J Haematol
; 188(2): 240-248, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31879945
12.
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
Lancet
; 393(10168): 229-240, 2019 01 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-30522922
13.
A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.
Blood
; 132(1): 49-58, 2018 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29666118
14.
The interval between progression and therapy initiation is the key prognostic parameter in relapsing diffuse large B cell lymphoma: analysis from the Czech Lymphoma Study Group database (NIHIL).
Ann Hematol
; 99(7): 1583-1594, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32506244
15.
First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients.
Ann Hematol
; 98(8): 1961-1972, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31065733
16.
Emergence of a lymphoma imitating an infectious infiltration surrounding the infrarenal aorta after EVAR.
Vasa
; 48(6): 531-534, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31271346
17.
Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial.
Lancet Oncol
; 19(11): 1530-1542, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30309758
18.
Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma.
Br J Haematol
; 180(2): 224-235, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29193019
19.
Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance.
Hematol Oncol
; 36(5): 773-778, 2018 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-30129045
20.
Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma.
Hematol Oncol
; 36(1): 110-115, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-29083050